Central Obesityw-bemsNCT07307898
Cavitaion vs W-BEMS on Central Obesity
A study testing cavitation, whole body electromyostimulation in people with Central Obesity, run by Cairo University at 1 site in Egypt.
Trial summary
The purpose of this study is to compare the effects of ultrasound cavitation and whole-body electromyostimulation (WB-EMS) on inflammatory markers in individuals with central obesity. Read more about this study
- Who is it for?
- Ages 18 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Central Obesity
- What is being tested?
- cavitation, whole body electromyostimulation
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteEgypt
- Study dates
- 5 Sep 2024to 4 Jan 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Adults aged 18-50 years.
- Individuals diagnosed with central obesity, defined as a waist circumference greater than 102 cm in men and 88 cm in women.
- Participants with a stable body weight for at least three months prior to the study.
- No engagement in regular physical activity or weight loss programs in the past six months.
- Willingness to adhere to study protocols and attend all scheduled sessions.
Who cannot join
- Individuals with chronic diseases other than obesity-related conditions, such as cardiovascular disease, diabetes, or severe hypertension.
- Pregnant or lactating women.
- Individuals with implanted electronic devices (e.g., pacemakers).
- Participants with dermatological conditions or skin infections in the treatment area.
- Individuals undergoing medication that may affect fat metabolism or inflammatory markers.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Cavitation Versus Whole-Body Electromyostimulation on Infilamatory Markers in Centeral Obesity
The purpose of this study is to compare the effects of ultrasound cavitation and whole-body electromyostimulation (WB-EMS) on inflammatory markers in individuals with central obesity.
Read the detailed description
Sixty individuals with central obesity were recruited from private clinics. And underwent a screening process to determine their eligibility based on the inclusion and exclusion criteria. Eligible participants were informed about the study details, procedures, potential risks, and benefits before obtaining written informed consent
- Conditions
- Central Obesity
- Being tested
- cavitation, whole body electromyostimulation
- Medical subject headings
- Obesity, Abdominal
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
cavitation, whole body electromyostimulationDevice
The duration of the study was set for 12 weeks. Assessments were meticulously conducted at both the baseline and the conclusion of the study period to evaluate outcomes across the different groups.
| Study group | Role | What they receive |
|---|---|---|
| group A (Study group) | Experimental | Participants in this cohort were administered localized ultrasound cavitation treatments. Each session was approximately 30 minutes in duration, with treatments scheduled twice a week. In addition, participants received mediterranean diet Receives: Device: cavitation, whole body electromyostimulation |
| group B (Study group) | Experimental | : Participants assigned to this cohort underwent whole- body electromyostimulation (WB-EMS) therapy. These sessions were 20 minutes long, also occurring twice weekly. Participants also received mediterranean diet. Receives: Device: cavitation, whole body electromyostimulation |
| Group C (Control Group) | Sham comparator | Participants in this control group receive mediterranean diet. Additionally, they participated in all assessment procedures, ensuring a comprehensive comparative analysis. Receives: Device: cavitation, whole body electromyostimulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Inflammatory Markers
Measurement of changes in levels of Tumor Necrosis Factor-alpha (TNF-alpha), and Interleukin-6 (IL-6) using ELISA (Enzyme-Linked Immunosorbent Assay) kits.
Measured: 3 Monthes
Secondary outcomes (3)
Waist Circumference
Will be measured at the level of the iliac crest using a standard measuring tape to assess changes in central adiposity.
Measured: 3 Monthes
Body Weight
Standard clinical scales to measure body weight at each visit to track changes over the study period.
Measured: 3 Monthes
Body Mass Index (BMI)
Will be calculated using measured height and weight (kg/m²) to observe changes in overall body mass classification.
Measured: 3 Monthes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Dec 2025
- Study start5 Sep 2024
- Primary completion5 Nov 2024
- Study completion4 Jan 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Central ObesityStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hadeer Elsayed Abdelrazik Elsayed Ramadan, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07307898
- Sponsor's protocol ID
- 012/005581
- Acronym
- w-bems
- Status last verified
- Dec 2025
- First submitted
- 26 Aug 2025
- Last updated
- 29 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cavitation Versus Whole-Body Electromyostimulation on Infilamatory Markers in Centeral Obesity
- ClinicalTrials.gov ID
- NCT07307898
- Acronym / sponsor ID
- w-bems / 012/005581
- Conditions
- Central Obesity
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 5 Sep 2024 (actual)
- Primary completion
- 5 Nov 2024 (actual)
- Study completion
- 4 Jan 2026 (estimated)
- First posted
- 29 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to compare the effects of ultrasound cavitation and whole-body electromyostimulation (WB-EMS) on inflammatory markers in individuals with central obesity.
Detailed description
Sixty individuals with central obesity were recruited from private clinics. And underwent a screening process to determine their eligibility based on the inclusion and exclusion criteria. Eligible participants were informed about the study details, procedures, potential risks, and benefits before obtaining written informed consent
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| group A (Study group) | Experimental | Device: cavitation, whole body electromyostimulationParticipants in this cohort were administered localized ultrasound cavitation treatments. Each session was approximately 30 minutes in duration, with treatments scheduled twice a week. In addition, participants received mediterranean diet |
| group B (Study group) | Experimental | Device: cavitation, whole body electromyostimulation: Participants assigned to this cohort underwent whole- body electromyostimulation (WB-EMS) therapy. These sessions were 20 minutes long, also occurring twice weekly. Participants also received mediterranean diet. |
| Group C (Control Group) | Sham comparator | Device: cavitation, whole body electromyostimulationParticipants in this control group receive mediterranean diet. Additionally, they participated in all assessment procedures, ensuring a comprehensive comparative analysis. |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Adults aged 18-50 years.
- Individuals diagnosed with central obesity, defined as a waist circumference greater than 102 cm in men and 88 cm in women.
- Participants with a stable body weight for at least three months prior to the study.
- No engagement in regular physical activity or weight loss programs in the past six months.
- Willingness to adhere to study protocols and attend all scheduled sessions.
Key exclusion criteria (5 listed)
- Individuals with chronic diseases other than obesity-related conditions, such as cardiovascular disease, diabetes, or severe hypertension.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| cavitation, whole body electromyostimulationThe duration of the study was set for 12 weeks. Assessments were meticulously conducted at both the baseline and the conclusion of the study period to evaluate outcomes across the different groups. | Device | Group C (Control Group), group A (Study group), group B (Study group) |
Primary outcome
Inflammatory Markers
Time frame: 3 Monthes
Measurement of changes in levels of Tumor Necrosis Factor-alpha (TNF-alpha), and Interleukin-6 (IL-6) using ELISA (Enzyme-Linked Immunosorbent Assay) kits.
3 secondary outcomes
Waist Circumference
Time frame: 3 Monthes
Body Weight
Time frame: 3 Monthes
Body Mass Index (BMI)
Time frame: 3 Monthes
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Dec 2025.
Related trials for Central Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Not yet recruiting
Compulsive Eating and Brain's Reward System in Different Pathologies
PARKINSON DISEASE (Disorder), Bipolar 1 Disorder
Active, not recruitingObservational study
A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti
Hypertension, Diabetes
Active, not recruiting
Developing a Learning COmmunity to Increase eNgagemeNt and Enrollment in Cardiovascular Clinical Trials (CONNECT)
Cardiovascular Diseases, Hypertension
Active, not recruiting
Influence of FreeO2 on Percentage of Time Within Oxygen Saturation Target Using Noninvasive Ventilation (NIV) and Continuous Positive Airway Pressure (CPAP) for Patients Admitted for AECOPD or Bariatric Surgery
COPD Exacerbation, Oxygen Toxicity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing cavitation, whole body electromyostimulation in people with Central Obesity, run by Cairo University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 29 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Inflammatory Markers (time frame: 3 Monthes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Dec 2025.